Wednesday, July 8, 2015

Merck revenue grows, but net income dips

Merck said its second-quarter revenue increased slightly, while net income dropped slightly, hurt by currency exchange rates.

Merck revenue grows, but net income dips

0 comments
Travel Deals

Merck said its second-quarter revenue increased slightly, while net income dropped slightly.

In announcing the results, Merck said its sales revenue increased about one percent, from $12.151 billion in 2011 to $12.311 billion in the second quarter of 2012, which ended on June 30.

The net income fell from $2.024 billion in 2011 to $1.793 billion in the same period.

Merck is based in Whitehouse Station, N.J., and has a big operation in West Point, Montgomery County.

More coverage
 
More 'PhillyPharma' posts

The second-quarter pharmaceutical sales revenue increased two percent to $10.6 billion, including a three percent negative impact due to foreign exchange.

The diabetes drugs Januvia and Janumet had the largest percentage growth. Januvia sales rose from $779 million to $1.058 billion, a 36 percent increase.

Asthma drug Singular was the top selling Merck drug, with $1.4 billion in sales, but that leadership spot will change by the end of the third quarter.

Singular loses patent protection next week. Merck executive vice president and president for global human health Adam Schechter said the company expects multiple generic companies to enter the market immediately, with declining Singular sales revenue being the result.

"It will be rapid and it will be significant," Schechter said.

CFO Peter Kellogg said the loss of high-margin profits from Singular will lower the expected gross profit margin for the rest of the year.

A link to Merck's announcement with numbers is here.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter